Celltrion Healthcare, Celltrion Group’s overseas sales unit, announced Tuesday that Vegzelma, Celltrion’s biosimilar referencing Roche's Avastin (bevacizumab), has been listed as a preferred drug on a formulary managed by Ventegra. “Through Ventegra's proprietary formulary program, which covers 13 million members in the US, Vegzelma will be able to increase its share in the US bevacizumab ...